Poor
Partially Aligned
Patient Risk:
Medium
Summary
Claims about indication and cholesterol-lowering are broadly consistent with the provided label excerpts, but multiple other claims are about pricing/insurance/discount programs not addressed in the provided FDA-approved prescribing information. The provided excerpts also do not support these non-label marketing/financial assertions.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a prescription medication used to lower cholesterol levels.
Supported indirectly by label excerpt describing lipid-altering therapy and adjunction to diet for hypercholesterolemia (INDICATIONS AND USAGE).
Unsupported Statements
Lipitor is used to prevent cardiovascular disease.
Provided excerpts discuss starting therapy in patients with CHD or multiple risk factors for CHD as adjunct to diet (INDICATIONS AND USAGE) but do not explicitly state 'prevent cardiovascular disease.'
The average cost of a 30-day supply of Lipitor without insurance can range from $150 to $300.
No pricing/cost information is present in the provided label excerpts.
Some insurance plans may not cover Lipitor or may require a higher copayment or coinsurance.
No insurance coverage/cost-sharing information is present in the provided label excerpts.
If you have a high deductible, you may need to pay a significant portion of the cost of Lipitor out-of-pocket before insurance kicks in.
No deductible/out-of-pocket information is present in the provided label excerpts.
Even with insurance, a copayment or coinsurance for Lipitor can range from 10% to 30% of the medication's cost.
No copayment/coinsurance percentages are present in the provided label excerpts.
Patients may be eligible for a discount on Lipitor with insurance.
No discount/eligibility statements related to payer arrangements are present in the provided label excerpts.
Pfizer offers a patient assistance program (PAP) for Lipitor that provides free or discounted medication to eligible patients.
No patient assistance program or Pfizer PAP information is present in the provided label excerpts.
Pfizer's Lipitor patient assistance program requires meeting certain income and insurance requirements.
No PAP eligibility requirements are present in the provided label excerpts.
Pfizer offers manufacturer coupons for Lipitor.
No manufacturer coupon information is present in the provided label excerpts.
Pfizer manufacturer coupons can be used in conjunction with insurance coverage.
No coupon usage rules are present in the provided label excerpts.
Discount cards can provide discounts on Lipitor.
No discount card information is present in the provided label excerpts.
Discount cards can be used in conjunction with insurance coverage.
No discount card usage rules are present in the provided label excerpts.
Generic alternatives to Lipitor include generic atorvastatin.
No generic/alternative product statements are present in the provided label excerpts.
Generic medications are often significantly cheaper than brand-name medications.
No comparative pricing information is present in the provided label excerpts.
Contradictions
Important Omissions
No label-based dosing and administration information was provided, despite claims being made about 'used to prevent cardiovascular disease' and other aspects; however, the user’s statements do not include dosing/admin requests.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
Non-label financial/coverage/assistance claims may mislead regarding access cost and eligibility, which can indirectly affect treatment continuity. These statements are not supported by the provided FDA label excerpts. No specific contraindication/warning misuse was stated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Several claims (pricing, insurance coverage/cost-sharing ranges, PAP/coupons/discount cards, and generic pricing) are not addressed in the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Limit claims to on-label content supported by the provided label excerpts (e.g., lipid-altering therapy as adjunct for hypercholesterolemia in indicated risk groups) and remove or clearly qualify non-label financial/access program information unless verified against authoritative sources outside the label.